Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet

Journal of Nutritional Biochemistry

Volumn 25, Issue 1, 2014, Pages 81-90

  Mattace Raso, Giuseppina ^a   Simeoli, Raffaele ^a   Iacono, Anna ^a,b   Santoro, Anna ^a   Amero, Paola ^a   Paciello, Orlando ^a   Russo, Roberto ^a   D'Agostino, Giuseppe ^a   Di Costanzo, Margherita ^a   Berni Canani, Roberto ^a   Calignano, Antonio ^a   Meli, Rosaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Glucose tolerance; Gut permeability; Inflammation; Insulin resistance; Non alcoholic fatty liver disease; Toll like receptor

Indexed keywords

ARABINOGALACTAN; B 21060; FRUCTOSE OLIGOSACCHARIDE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; SERINE; SUPPRESSOR OF CYTOKINE SIGNALING 3; SYNBIOTIC AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET RESTRICTION; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; ENTEROBACTERIALES; ESCHERICHIA COLI; FAT INTAKE; GENE EXPRESSION; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; INJURY SEVERITY; INSULIN RESISTANCE; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS PARACASEI; LIPID DIET; LIVER; LIVER INJURY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; PEROXISOME; PHOSPHORYLATION; PROTEIN EXPRESSION; RAT; STEATOSIS;

GLUCOSE TOLERANCE; GUT PERMEABILITY; INFLAMMATION; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE; TOLL-LIKE RECEPTOR;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; DIET, HIGH-FAT; DOWN-REGULATION; ENTEROBACTERIACEAE; FATTY LIVER; GALACTANS; GLUCOSE TRANSPORTER TYPE 4; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; INTESTINAL MUCOSA; LACTOBACILLUS; LIVER; MALE; OLIGOSACCHARIDES; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; SYNBIOTICS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9;

EID: 84889571833     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.09.006     Document Type: Article

References (53)

1. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846.
2. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114:842-845.
3. Ruan H., Lodish H.F. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003, 14:447-455.
4. Senn J.J., Klover P.J., Nowak I.A., et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003, 278:13740-13746.
5. Abu-Shanab A., Quigley E.M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010, 7:691-701.
6. Musso G., Gambino R., Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol 2010, 21:76-83.
7. Iacono A., Mattace Raso G., Berni Canani R., et al. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 2011, 22:699-711.
8. Kirpich I.A., McClain C.J. Probiotics in the treatment of the liver diseases. J Am Coll Nutr 2012, 31:14-23.
9. Frasinariu OE, Ceccarelli S, Alisi A et al. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis. 2012. doi:pii: S1590-8658(12)00430-6. http://dx.doi.org/10.1016/j.dld.2012.11.010.
10. Gareau M.G., Sherman P.M., Walker W.A. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010, 7:503-514.
11. Gómez-Llorente C., Muñoz S., Gil A. Role of Toll-like receptors in the development of immunotolerance mediated by probiotics. Proc Nutr Soc 2010, 69:381-389.
12. Esposito E., Iacono A., Bianco G., et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 2009, 139:905-911.
13. Vajro P., Mandato C., Licenziati M.R., et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011, 52:740-743.
14. Matsuzaki T., Yamazaki R., Hashimoto S., et al. Antidiabetic effects of an oral administration of lactobacillus casei in a non-insulin-dependent diabetes mellitus (NIDDM) model using KK-Ay mice. Endocr J 1997, 44:357-365.
15. Matsuzaki T., Nagata Y., Kado S., et al. Effect of oral administration of lactobacillus casei on alloxan-induced diabetes in mice. APMIS 1997, 105:637-642.
16. Tabuchi M., Ozaki M., Tamura A., et al. Antidiabetic effect of lactobacillus GG in streptozotocin-induced diabetic rats. Biosci Biotechnol Biochem 2003, 67:1421-1424.
17. Cani P.D., Neyrinck A.M., et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007, 50:2374-2383.
18. Yadav H., Jain S., Sinha P.R. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 2007, 23:62-68.
19. Yun S.I., Park H.O., Kang J.H. Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. J Appl Microbiol 2009, 107:1681-1686.
20. Lye H.S., Kuan C.Y., Ewe J.A., et al. The improvement of hypertension by probiotics: effects on cholesterol, diabetes, renin and phytoestrogens. Int J Mol Sci 2009, 10:3755-3775.
21. Ibnou-Zekri N., Blum S., Schiffrin E.J., et al. Divergent patterns of colonization and immune response elicited from two intestinal Lactobacillus strains that display similar properties in vitro. Infect Immun 2003, 71:428-436.
22. Passariello A., Terrin G., Cecere G., et al. Randomised clinical trial: efficacy of a new synbiotic formulation containing Lactobacillus paracasei B21060 plus arabinogalactan and xilooligosaccharides in children with acute diarrhoea. Aliment Pharmacol Ther 2012, 35:782-788.
23. Mileti E., Matteoli G., Iliev I.D., et al. Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One 2009, 4:e7056.
24. Morelli L., Zonenschain D., Callegari M.L., et al. Assessment of a new synbiotic preparation in healthy volunteers: survival, persistence of probiotic strains and its effect on the indigenous flora. Nutr J 2003, 2:11-17.
25. Surwit R., Feinglos M., Rodin J., et al. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 1995, 44:645-651.
26. Svegliati-Baroni G., Candelaresi C., Saccomanno S., et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006, 169:846-860.
27. Itaya K., Ui M. Colorimetric determination of free fatty acids in biological fluids. J Lipid Res 1965, 6:16-20.
28. de La Serre C.B., Ellis C.L., Lee J., et al. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol 2010, 299:G440-G448.
29. Shi H., Kokoeva M.V., Inouye K., et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116:3015-3025.
30. Hotamisligil G.S., Peraldi P., Budavari A., et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996, 271:665-668.
31. Cai D., Yuan M., Frantz D.F., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005, 11:183-190.
32. Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
33. Xu A., Wang Y., Keshaw H., et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112:91-100.
34. Kamada Y., Tamura S., Kiso S., et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003, 125:1796-1807.
35. Harano Y., Yasui K., Toyama T., et al. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 2006, 26:613-620.
36. Inagaki T., Dutchak P., Zhao G., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007, 5(6):415-425.
37. Woo Y.C., Xu A., Wang Y., Lam K.S. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf) 2013, 78:489-496.
38. Badman M.K., Pissios P., Kennedy A.R., et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007, 5:426-437.
39. Neschen S., Morino K., Rossbacher J.C., et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 2006, 55:924-928.
40. Gurnell M. PPARgamma and metabolism: insights from the study of human genetic variants. Clin Endocrinol. 2003, 59:267-277.
41. Chatterjee P.K. Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation. Br J Pharmacol 2010, 160:1889-1891.
42. Mencin A., Kluwe J., Schwabe R.F. Toll-like receptors as targets in chronic liver diseases. Gut 2009, 58:704-720.
43. Amar J., Chabo C., Waget A., et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011, 3:559-572.
44. Lupp C., Robertson M.L., Wickham M.E., et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007, 2:119-129.
45. Delzenne N.M., Cani P.D. Gut microbiota and the pathogenesis of insulin resistance. Curr Diab Rep 2011, 11:154-159.
46. De Bandt J.P., Waligora-Dupriet A.J., Butel M.J. Intestinal microbiota in inflammation and insulin resistance: relevance to humans. Curr Opin Clin Nutr Metab Care 2011, 14:334-340.
47. Romeo J., Nova E., Wärnberg J., et al. Immunomodulatory effect of fibres, probiotics and synbiotics in different life-stages. Nutr Hosp 2010, 25:341-349.
48. Schwabe R.F., Seki E., Brenner D.A. Toll-like receptor signaling in the liver. Gastroenterology 2006, 130:1886-1900.
49. De Almeida I.T., Cortez-Pinto H., Fidalgo G., et al. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr 2002, 21:219-223.
50. Li L., Chen L., Hu L., et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 2011, 54:1620-1630.
51. Miura K., Seki E., Ohnishi H., et al. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2010, 2010:362847.
52. Ehses J.A., Meier D.T., Wueest S., et al. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 2010, 53:1795-1806.
53. Miura K., Kodama Y., Inokuchi S., et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010, 139:323-334.